NexMed Announces Pre-Clinical Study Showing Vitaros® Significantly Promotes Wound Healing
12 Mayo 2010 - 3:30PM
Business Wire
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of
products based on the NexACT® technology, today announced results
from a pre-clinical study showing that Vitaros®, the
Company’s NexACT-based alprostadil product, significantly promoted
healing of deep tissue wounds. Specifically, in a pig model,
subjects with deep tissue wounds that were administered 200 mcgs of
Vitaros healed four times faster than those receiving placebo over
a 21-day period. This deep-seeded, wound healing pig model is
widely regarded as the gold standard for pre-clinical testing of
efficacy of wound-healing treatments. Vitaros is currently in
late-stage development for the treatment of erectile
dysfunction.
Bassam Damaj, Ph.D., President and Chief Executive Officer of
NexMed, stated, “Poor blood supply is often a major factor in
patients with healing failure. Alprostadil is a well known
vasodilator which can enhance local microcirculation by inducing
capillary dilation and neovascularization. The aim of our study was
to test the safety and efficacy of Vitaros and its potential to
promote wound healing in a long-term pre-clinical model. These
initial results were very encouraging and warrant further testing
of our NexACT-based alprostadil product in human clinical
trials.”
NexMed also announced today that management will hold a
conference call to discuss 2010 first quarter financial results and
ongoing corporate activities, on Friday, May 14, 2010 at 12:00 p.m.
EDT. The call can be accessed in the U.S. by dialing (877) 407-8031
and outside of the U.S. by dialing (201) 689-8031 and asking the
conference operator for the NexMed Conference Call. The
teleconference replay will be available for one week by dialing
(877) 660-6853 within the U.S., and outside of the U.S. by dialing
(201) 612-7415. Replay pass codes 286 and 350779 are both required
for playback. The conference call will also be available live, via
Webcast, at:
http://www.investorcalendar.com/IC/CEPage.asp?ID=158530. The
Webcast replay will be available for three months following the
event.
About NexMed
NexMed is the largest specialty CRO based in San Diego, CA and
is one of the industry's most experienced CROs for in vitro and in
vivo pharmacology services and research models. The Company’s goal
is to generate revenues from the growth of its Discovery
Pre-clinical CRO business, while aggressively seeking to monetize
its proprietary NexACT® drug delivery technology through
out-licensing agreements with pharmaceutical and biotechnology
companies, worldwide. At the same time, NexMed is actively pursuing
partnering opportunities for its NexACT®-based treatments for
onychomycosis, psoriasis, sexual dysfunction and cancer. For
further information on NexMed and its subsidiaries, visit the
following websites: http://www.nexmed.com or
http://www.bio-quant.com.
Forward-Looking Statement Safe
Harbor for NexMed
Statements under the Private Securities Litigation Reform Act:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company
including but not limited to its ability to replicate pre-clinical
results in human clinical trials.
Nexmed (MM) (NASDAQ:NEXM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Nexmed (MM) (NASDAQ:NEXM)
Gráfica de Acción Histórica
De May 2023 a May 2024